Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia | fatcat!

by W. Zeijlemaker, G.J. Schuurhuis

Cited By

References to this release by other works.

Read more about quality, completeness, and caveats in the fatcat guide.

Showing 1 - 4 of 4 references (in 156ms)
via fatcat-crossref	Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant [chapter] Curtis Lachowiez, Rachel J. Cook 2021 Blood and Marrow Transplant Handbook doi:10.1007/978-3-030-53626-8_15
via grobid	Is Need Chemotherapy Titration During Acute Myeloid Leukemia Treatment? Ali Amanati, Assistant Professor of Pediatric infectious disease, Dr Alborzi Research center, Shiraz University of Medical Sciences, Shiraz, Iran 2021 Journal of Oncology Research Review & Reports doi:10.47363/jonrr/2021(2)131	web.archive.org [PDF]
via grobid	MINIMAL RESIDUAL DISEASE ASSESMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA BY MULTICOLOUR FLOW CYTOMETRY (LITERATURE REVIEW) T. I. Lobanova, I. V. Galtseva, E. N. Parovichnikova 2018 Onkogematologiâ doi:10.17650/1818-8346-2018-13-1-83-102	web.archive.org [PDF]
via crossref	CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia Bas Kersten, Matthijs Valkering, Rolf Wouters, Rosa van Amerongen, Diana Hanekamp, Zinia Kwidama, Peter Valk, Gert Ossenkoppele (+ more) 2016 British Journal of Haematology doi:10.1111/bjh.13941 pmid:26814163
JSON